British Cardiovascular Intervention Society Consensus Position Statement on Out-of-hospital Cardiac Arrest 2: Post-discharge Rehabilitation.

Out-of-hospital cardiac arrest (OHCA) is a major public health issue that poses significant challenges both in immediate management and long-term follow-up. Survivors of OHCA often experience a combination of complex medical, physical and psychological needs that have a significant impact on quality of life. Guidelines suggest a multi-dimensional follow-up to address both physical and non-physical domains for survivors. However, it is likely that there is substantial unwarranted variation in provision of services throughout the UK. Currently, there is no nationally agreed model for the follow-up of OHCA survivors and there is an urgent need for a set of standards and guidelines in order to ensure equal access for all. Accordingly, the British Cardiovascular Interventional Society established a multi-disciplinary working group to develop a position statement that summarises the most up-to-date evidence and provides guidance on essential and desirable services for a dedicated follow-up pathway for survivors of OHCA.
Competing Interests: Disclosure: NC is President of the British Cardiovascular Intervention Society and is on the editorial board of Interventional Cardiology: Reviews, Research, Resources; this did not influence peer review. In the last 36 months; NC has received grants from Haemonetics, HeartFlow, Boston Scientific and Beckmann Coulter Diagnostics and speaker fees from Abbott, Boston Scientific and Edwards. JD has received speaker fees from AstraZeneca. NP has received grants from Heart Research UK. TK has received grants from Abbott Vascular and Treumo, consulting fees from BD and honoraria from AstraZeneca and Abbott Vascular. TQ has received grants from the National Institute for Health Research and the British Cardiovascular Society and is a Non-Executive Director of the NHS Ambulance Trust and Trustee for the British Association for Immediate Care. VO has received speaker fees from Bristol Myers Squibb and Pfizer. All other authors have no conflicts of interest to declare. Funding: This work was partly funded by a King's College Hospital R & D Grant and was supported by the Department of Health through a National Institute for Health Research Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust, UK.
(Copyright © 2022, Radcliffe Cardiology.)